Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: Tunica Albuginea who wrote (4299)	1/4/1998 7:05:00 PM
From: Gene Voss	Read Replies (3) \| Respond to of 23519

TA: Almost all comparisons of Muse to injections use a combination in the injectable.This technique will obviously show greater efficacy with the parenteral therapy. The combination transurethrally will also show greater efficacy and has always been part of the Muse strategy.Eventually a combination of as many as 3 agents with different mechanisms of action can be used so efficacy ranges approaching injection without the needle should be possible. Viagras single system almost by definition will never approach these levels of efficacy.My opinion is that Pfizer is doing a great job of controlling this market by carefully allowing positive anecdotal statements from its researchers and satisfied patients while limiting disclosure of details of the studies .The current situation in medicine lends itself to this control of data since private funding sources pay the price of continuing research.All drug companies have the power to dictate when and where a study result will be presented.I expect no peer reviewed articles will appear until FDA approval since the information in the studies will be critisized if its not absolutely pristine. I certainly look forward to having Viagra under the extreme scrutiny Muse has recieved.Remember no drug is ever as efficacious as it is in its clinical trials. GV